Global Blood Therapeutics Inc (GBT) Major Shareholder Purchases $6650000.00 in Stock

Mae Love
January 13, 2018

Zacks Investment Research lowered Global Blood Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, October 16th. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

GBT has been the subject of several research reports. Currently, the stock has a 1 Year Price Target of $68.42. HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a "buy" rating in a research report on Monday, December 11th. Wedbush initiated the shares of GBT in report on Tuesday, September 8 with "Outperform" rating. BidaskClub upgraded shares of Global Blood Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, December 12th.

In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the stock in a transaction dated Monday, October 30th. Finally, DekaBank Deutsche Girozentrale purchased a new position in Global Blood Therapeutics during the second quarter valued at approximately $211,000. The stock was acquired at an average price of $38.00 per share, with a total value of $6,650,000.00. Following the completion of the transaction, the insider now owns 140,055 shares in the company, valued at $4,201,650. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The Company's Post-Secondary segment offers various doctoral, masterÂ's, and bachelorÂ's online programs for working adults in business and technology, education, nursing and health sciences, public service leadership, social and behavioral sciences, and undergraduate studies markets; and learning courses that are eligible for transfer into credit at approximately 2,000 colleges and universities. The disclosure for this purchase can be found here. Parametric Portfolio Associates LLC now owns 30,943 shares of the company's stock worth $846,000 after buying an additional 284 shares during the period.

Investors Focus on Technical Levels of Global Blood Therapeutics Inc.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. Vanguard Group Inc. now owns 2,933,251 shares of the company's stock valued at $80,224,000 after acquiring an additional 397,271 shares during the period. Trexquant Investment LP purchased a new position in Global Blood Therapeutics during the third quarter valued at approximately $202,000. The insider, PERCEPTIVE ADVISORS LLC, now holds 4.89 million shares of GBT. Bank of America Corp DE grew its holdings in shares of Global Blood Therapeutics by 103.6% during the 1st quarter. The company's institutional ownership is monitored at 13.64 percent. (NASDAQ:GBT) tinted gains of +1.8% (+1 points) to US$56.45. About 5.09 million shares traded or 311.10% up from the average. Global Blood Therapeutics Inc has a twelve month low of $14.70 and a twelve month high of $57.75. (GBT) will report its next earnings on Feb 01 AMC.

Revenue Approximations Analysis: NVIDIA Corporation (NVDA), Sprint Corporation (S)
Cambridge Advisors reported 0.25% of its portfolio in NVIDIA Corporation ( NASDAQ : NVDA ). 76,755 are held by Fiera Cap Corp. The Princeton Portfolio Strategies Group Llc holds 153,584 shares with $6.55 million value, up from 138,595 last quarter.

Sit Investment Associates Inc. Cuts Position in Becton Dickinson and Co (BDX)
ClariVest Asset Management LLC acquired a new position in Becton, Dickinson and Company during the second quarter worth $170,000. Ferguson Wellman Capital Management Inc increased Becton Dickinson & Co ( BDX ) stake by 1075.28% reported in 2017Q3 SEC filing.

Warner Bros. Teases "Teen Titans GO! To The Movies"
In the film, Robin (voiced by Scott Menville ) is determined to see the Teen Titans get their own movie. And there's a 15-second fart joke that takes up one-third of this trailer.

The company reported its EPS on 9/29/2017. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. equities analysts forecast that Global Blood Therapeutics will post -2.54 EPS for the current year.

WARNING: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & global copyright and trademark law. Global Blood Therapeutics, based in South San Francisco, California.

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders.

"On Tuesday, Global Blood announced that the FDA has granted Breakthrough Therapy Designation (BTD) to its lead product, voxelotor (a.k.a. GBT440), in sickle cell disease (SCD)".

Other reports by

Discuss This Article